Table 1.
Detailed clinical information of patients and controls enrolled in this study.
| ID number | Biopsy location | Sex | Age at sampling | Current age | Age of death | Clinical status | Genetic status |
|---|---|---|---|---|---|---|---|
| SALS 1 | Arm | M | 48 | NA | NA | Affected | No known ALS-associated mutations |
| SALS 2 | Arm | M | 62 | NA | NA | Affected | No known ALS-associated mutations |
| SALS 3 | Arm | M | 81 | NA | NA | Affected | No known ALS-associated mutations |
| FALS1 | Arm | F | 63 | 65 | NA | Clinically unaffected | C9orf72 expansion |
| FALS2 | Arm | F | 47 | 49 | NA | Clinically unaffected | C9orf72 expansion |
| FALS3 | Arm | F | 59 | 60 | NA | Affected | C9orf72 expansion |
| NFM1 | Arm | M | 25 | 26 | NA | Affected | NA |
| NFM2 | Arm | M | 26 | 27 | NA | Affected | NA |
| NFM3 | Arm | F | 22 | 23 | NA | Affected | NA |
| CTRL 1 | Arm | F | 68 | 69 | NA | Control | NA |
| CTRL 2 | Arm | M | 23 | 39 | NA | Control | NA |
| CTRL 3 | Arm | M | 29 | 45 | NA | Control | NA |
SALS, Sporadic ALS; FALS, Familial ALS; NFM, Neurofibromatosis type 1; CTRL, Control; M, Male; F, Female; NA, not applicable or info not available.